Department of Defense (DoD) Comments on the Interagency Science Discussion Draft IRIS Assessment of Benzo[a]pyrene November 2016 (Date Received: December 14, 2016)

			Department of Defense Comments	son					
IRIS Toxicological Review of Benzo(a)pyrene, Step 6b Review									
(Comments are based on the redline strikeout version)									
Comments submitted by: OASD(EI&E), ESOH Directorate, CMRM Program			Organization: Department of Defense	Date Submitted: 12/14/2016					
	-	or methods (S); Editon nentation of the asses		or Other (O). Also please indicate if Major i.e. affects	s the				
Comment No.	Section	Pages	Comment	Suggested Action, Revision and References (if necessary)	*Category				
1	Preamble, Section 3	XXV	PECO statements (Populations, Exposures, Comparisons, Outcomes) are said to govern literature searches text added to the Preamble. However, in the benzo(a)pyrene (BaP) document we do not see the PECO statements used for the BaP literature search.	Suggest adding a disclaimer or footnotes noting which of the procedures described in the Preamble were not utilized in the BaP Toxicological Review.	E/M				
2	Preface	xvii, line 23	http://www.epa.gov/pbt/pubs/benzo.htm hyperlink is not a valid website. Clicking on the hyperlink takes the reader to a "Page Not Found" EPA page.	Provide active link.	0				
3	ES and General	xv and numerous locations	Hyperlinks to the EPA HERO website required pre-registration.	Ensure that links in the version released to the public are to the appropriate website.	0				
4	2.2.3	2-32	The text states that the Wu et al. (2003a) had a 19% decrease in fetal survival, whereas Table 2.4 states 10% and earlier text on page F-16 and Appendix F states 9%.	Please correct to be accurate reflection of results as published.	E				

5	Appendix F	F-16, lines 25 -	In Appendix D the summary of Wu et al (2003a)	Please describe why the conclusions as presented	S/M
0		36	notes that "The number of resorptions at 75 and	by Wu et al. were not presented and used in	
			$100 \ \mu\text{g/m}^3$, but not at 25 $\ \mu\text{g/m}^3$, was statistically	Tables 2-4 and 2-5 as a NOAEL. Please increase	
			significantly increased compared with controls."	the clarity and transparency surrounding the	
			But in response to the SAB comments in	further analysis of the data from Wu et al. Please	
			Appendix F "an apparent decrease in fetal	cite the further analysis and if EPA performed it,	
			survival of approximately 9% (relative to the	include the analysis in an appendix. If EPA	
			pooled carbon black control groups) at 25	obtained the data please further justify why dose	
			µg/m ³ ." is described. It appears that another	response modeling was not performed using it.	
			group, perhaps EPA, performed this analysis. If		
			EPA were able to obtain the data to perform this		
			analysis (we noted Wu et al. was an NIH funded		
			study, so perhaps the data were available) and		
			perform the pooled control analysis perhaps		
			BMD modeling would be possible. We		
			acknowledge that further analysis of Wu et al.		
			was recommended by the SAB.		
6	Table E-18	E-54	The table states: "Polynomial 2° had the lowest	How does EPA determine when the lowest AIC	S
			AIC. However, the BMDL at 1% was	should be rejected, i.e., how is a value determined	
			excessively low. No model was selected." It is	to be "excessively low"? If our understanding is	
			our understanding that, if the other criteria are	correct and there was a deviation from the	
			met, IRIS always selects the lowest AIC	standard practice, it should be described and	
				justified in the main body of the text in addition to	
				being noted in the Appendix table. Also, we note	
				that the BMDL was excessively low but we	
				understand that the BMDL selected can be such	
				that it is in the observable range.	